Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Accumulated Depreciation: 2022-2024

Historic Accumulated Depreciation for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $3.6 million.

  • Taysha Gene Therapies' Accumulated Depreciation rose 12.03% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 12.03%. This contributed to the annual value of $3.6 million for FY2024, which is 20.31% up from last year.
  • As of FY2024, Taysha Gene Therapies' Accumulated Depreciation stood at $3.6 million, which was up 20.31% from $3.0 million recorded in FY2023.
  • In the past 5 years, Taysha Gene Therapies' Accumulated Depreciation ranged from a high of $3.6 million in FY2024 and a low of $1.6 million during FY2022.
  • Moreover, its 3-year median value for Accumulated Depreciation was $3.0 million (2023), whereas its average is $2.7 million.
  • Data for Taysha Gene Therapies' Accumulated Depreciation shows a peak YoY soared of 81.43% (in 2023) over the last 5 years.
  • Over the past 3 years, Taysha Gene Therapies' Accumulated Depreciation (Yearly) stood at $1.6 million in 2022, then spiked by 81.43% to $3.0 million in 2023, then grew by 20.31% to $3.6 million in 2024.